Nutriband's Dividend Announcement for Preferred Stock Holders
Nutriband Inc. (NASDAQ: NTRB, NTRBW) is making waves with an exciting update for its shareholders regarding the upcoming 25% preferred stock dividend. This announcement is crucial for individuals holding shares and captures their attention as key dates approach.
Key Dates to Remember
Shareholders on record as of July 25 will soon receive a preferred share for every four shares of common stock that they own. This substantial dividend payout highlights the company's dedication to enhancing shareholder value. The official pay date for these preferred shares will be August 5, giving investors crucial insight into when they can expect their rewards.
Conversion of Preferred Shares
Each preferred share distributed will allow for conversion into a single share of common stock, contingent upon the FDA’s approval of Nutriband's groundbreaking AVERSA Fentanyl product. This conversion offers a strategic advantage for investors who anticipate strong performance from Nutriband's innovative offerings.
Dividend Rights for Preferred Shares
Should the new preferred shares remain unconverted, they will entitle holders to a cash dividend, which will be paid out from the company's profits on an annual basis, subject to the discretion of the board of directors. This reinforces Nutriband's commitment to providing ongoing returns to its investors, even if conversion does not occur.
About AVERSA™ Technology
Nutriband's AVERSA™ abuse-deterrent transdermal technology represents a significant innovation in pain management solutions. By integrating aversive agents into transdermal patches, this technology aims to combat abuse, diversion, misuse, and unintended exposure to potentially harmful drugs. The potential impacts of AVERSA™ technology are essential for ensuring that vital medications, especially fentanyl, remain accessible to patients who genuinely need them.
Company Overview
Nutriband Inc. is at the forefront of developing transdermal pharmaceutical products. Their lead product focuses on an abuse-deterrent fentanyl patch, leveraging the advantages of AVERSA™ technology. This technology can be crucial in the fight against drug abuse, addressing a significant healthcare challenge by preventing misuse while ensuring legitimate access for patients.
Contact Information
For more information, Nutriband invites inquiries through their phone at 407-377-6695 or email at info@nutriband.com. Their dedication to transparency and investor relations is reflected in their proactive communication.
Frequently Asked Questions
What is the preferred stock dividend announced by Nutriband?
Nutriband announced a 25% preferred stock dividend, with shareholders receiving preferred shares based on their common stock ownership.
When will the preferred stock dividend be paid?
The pay date for the preferred stock dividend is set for August 5.
What is the significance of the preferred shares?
Preferred shares will be convertible into common stock upon FDA approval of Nutriband's AVERSA product, enhancing their value for investors.
What is AVERSA technology?
AVERSA™ is an innovative abuse-deterrent transdermal technology designed to prevent misuse of certain pharmaceutical products, such as fentanyl patches.
How can shareholders contact Nutriband for more information?
Shareholders can contact Nutriband via phone at 407-377-6695 or email info@nutriband.com for inquiries and updates.
